Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Latest Information Update: 01 Jan 2024
At a glance
- Drugs AT 101 (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 26 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Jul 2023 Planned End Date changed from 15 Jun 2023 to 1 Dec 2024.
- 04 Jan 2023 Planned End Date changed from 15 Dec 2022 to 15 Jun 2023.